Nektar Therapeutics
Oligomer-beta blocker conjugates

Last updated:

Abstract:

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.

Status:
Grant
Type:

Utility

Filling date:

15 Feb 2019

Issue date:

5 Jan 2021